Books in the Current Clinical Oncology series

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development.

There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009.

The rationale for using intraoperative irradiation (IORT) is based on the realization that tolerable doses of eternal beam radiation are often insufficient to achieve control of locally advanced malignancies.

This book focuses on putting successful molecular strategies into practice for the treatment of gynecologic cancer. It approaches research into the pathology and treatment of gynecologic oncology from both clinical and experimental perspectives. This new volume will be necessary reading for clinicians and experimental researchers alike.

As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities.

This book offers insight into an intriguing group of rare cancers, examining a surge of recent advances in genetics and molecular biology, and offering instruction in new modalities of treatment. Coverage includes chemotherapy, surgical management, and more.

Rectal Cancer: International Perspectives on Multimodality Management is a timely analysis of the diagnosis, staging, pathology, and therapy of cancer of the rectum.

This book presents the forefront in the science and clinical management of myeloma bone disease. Coverage begins with sections on clinical presentation, imaging, and biochemical markers and goes on to discuss radiation, surgical, and medical therapies.

The rapid growth in the number of options available for the management of colorectal cancer presents the clinician with new opportunities and new complexities.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction.

These authors bring together the latest thinking from diverse fields of medicine to provide, in one volume, a guide to coordinated management of all aspects of spinal tumors covering chemo- and radiation therapy, pain management, diagnostic radiology, as well as reconstructive surgery and palliative care.

As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.

* Hepatocellular carcinoma (HCC) used to be regarded as a rare disease.

Describing the unique biological features of indolent hematologic neoplasms, this work provides insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease.

This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject.

A clinical case-based handbook has a role in general clinicians' practice of caring for patients with serious or life-limiting illness. Thus, we hope that the cases, key points, and practical tips will help health care providers who are not experts already in palliative care in the care of patients with serious illness and challenging problems.

Provides a variety of treatment options available for the management of breast cancer patients. This work reviews the clinical aspects of breast cancer, including, epidemiology and risk factors, breast imaging, biopsy techniques, breast-conserving surgery and reconstruction, mastectomy, and developments in radiation, hormonal, and chemotherapy.

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development.

This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject.

Leading expert physicians and investigators from around the world review the state-of-the-art in the management of squamous cell head and neck cancer, with emphasis on coordinating different treatment modalities.

This history of cancer patient surveillance after curative-intent treatment covers methodologies used in the past and present, the rationale behind them, likely future methodologies, the cost of surveillance, definitions of terms used in the field, and more.

Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics.

Finally, a role for che- therapy had finally become established, principally through phase III studies c- paring chemotherapy to radiation in mostly locally advanced stages III and IV that had undergone resection.

Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma.

The contributors offer not only an understandable description of its molecular origins-an essential key to developing future therapies and preventive measures-but also rigorously discuss well-tested approaches, as well as those that are currently being evaluated for future use in both the laboratory and clinic.

Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics.